共 50 条
- [41] INCB090244, A POTENT SMALL MOLECULE THAT INHIBITS THE PD-L1/PD-1 AXIS AND FUNCTIONS SIMILARLY TO PD-L1 ANTIBODIESJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A247 - A247Rios-Doria, JonathanVolgina, AllaGokhale, PrafullaLiu, HaoStevens, ChristinaZolotarjova, NinaDiMatteo, DarliseKapilashrami, KanishkBehshad, ElhamThekkat, PramodYang, GengjieHall, LeslieKanellopoulou, ChrysiRupar, MarkMaddage, ChristopherHorsey, AprilBurke, KristaYang, Yan-ouCovington, MaryanneWang, SteveLiu, PhillipWynn, RichardReardon, DavidKoblish, Holly
- [42] Augmenting Adoptive T-cell Immunotherapy by Targeting the PD-1/PD-L1 AxisCANCER RESEARCH, 2021, 81 (23) : 5803 - 5805Lai, JunyunBeavis, Paul A.Li, JasmineDarcy, Phillip K.
- [43] Targeting the PD-1/PD-L1 axis in non-small cell lung cancerCURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 111 - 124Kumar, RajivCollins, DearbhaileDolly, SaoirseMcDonald, FionaO'Brien, Mary E. R.Yap, Timothy A.
- [44] Author Correction: Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylationNature Communications, 15 (1)Chengyu ShiYing WangMinjie WuYu ChenFangzhou LiuZheyuan ShenYiran WangShaofang XieYingying ShenLingjie SangZhen ZhangZerui GaoLuojia YangLei QuZuozhen YangXinyu HeYu GuoChenghao PanJinxin CheHuaiqiang JuJian LiuZhijian CaiQingfeng YanLuyang YuLiangjing WangXiaowu DongPinglong XuJianzhong ShaoYang LiuXu LiWenqi WangRuhong ZhouTianhua ZhouAifu Lin
- [45] The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signalingCELL COMMUNICATION AND SIGNALING, 2024, 22 (01)Li, TianyeNiu, MengkeZhou, JianweiWu, KongmingYi, Ming
- [46] The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signalingCell Communication and Signaling, 22Tianye LiMengke NiuJianwei ZhouKongming WuMing Yi
- [47] Vascular Targeting Viral Therapy Augments Pd-L1 Checkpoint Blockade Anti-Tumor ActivityMOLECULAR THERAPY, 2017, 25 (05) : 270 - 271Breitbart, EyalMendel, ItzhakYacov, Niva
- [48] Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1096 - 1108Guo, JiazhengYu, FengyiZhang, KuojunJiang, ShengZhang, XiangyuWang, Tianyu
- [49] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumabScientific Reports, 7Hyun Tae LeeJu Yeon LeeHeejin LimSang Hyung LeeYu Jeong MoonHyo Jeong PyoSeong Eon RyuWoori ShinYong-Seok Heo
- [50] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumabSCIENTIFIC REPORTS, 2017, 7Lee, Hyun TaeLee, Ju YeonLim, HeejinLee, Sang HyungMoon, Yu JeongPyo, Hyo JeongRyu, Seong EonShin, WooriHeo, Yong-Seok